Both conditions may require hospitalization or surgical intervention
The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) followed over 9,000 patients for a median of 3.8 years and reported similar cancer rates between liraglutide and placebo groups
Many users find 0.1 mg provides meaningful benefits, and jumping to higher doses does not necessarily improve results
Research Diets, D12108 C, 1.25% cholesterol) or an ALC-supplemented diet (600 mg/kg, Changzhou Shuiyushuer Company, Changzhou, China) for 8 weeks (Control group, n = 4
Instead, they often peaked during titration and then levelled off, meaning that once participants were settled into their maintenance schedule, side effects tended to diminish rather than worsen